Are Bliss GVS Pharma latest results good or bad?

Bliss GVS Pharma has reported its financial results for the quarter ending March 2025, revealing several operational challenges. The company experienced a slight decline in net sales year-on-year, with a growth rate of -0.07% compared to the previous year’s 7.22%. This stagnation in sales is coupled with a significant drop in profit before tax, which stands at Rs 11.37 crore, reflecting a year-on-year decrease of 42.14%.
Profit after tax has also shown a decline, recorded at Rs 15.54 crore, down 22.5% from the same period last year. Additionally, the company faced a notable rise in interest costs, which increased by 55.56% quarter-on-quarter to Rs 1.68 crore, indicating a higher reliance on borrowings.

Operating profit has reached its lowest level in five quarters at Rs 21.09 crore, with an operating profit margin of just 10.65%. Furthermore, a significant portion of the profit before tax, approximately 51.49%, is derived from non-operating income, raising concerns about the sustainability of Bliss GVS Pharma's core business operations.

Overall, the financial performance for this quarter underscores substantial challenges for Bliss GVS Pharma, leading to an adjustment in its evaluation.